In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...
Hosted on MSN
Recent Developments in Diffuse Large B-Cell Lymphoma
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...
An innovative approach could transform the treatment landscape for DLBCL patients, offering hope to those who might otherwise ...
For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...
- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent need ...
CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma. Results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback